Welcome to our dedicated page for Remegen news (Ticker: REGMY), a resource for investors and traders seeking the latest updates and insights on Remegen stock.
RemeGen Co., Ltd. develops biopharmaceutical products, including antibody-drug conjugates, bispecific antibodies and fusion-protein biologics for autoimmune disease, oncology and ophthalmology. News for REGMY centers on telitacicept (RC18/泰爱®), disitamab vedotin (RC48/爱地希®), RC28-E and RC148, with recurring updates on clinical data, medical-conference presentations, licensing agreements and regulatory decisions.
Company announcements have covered NMPA approvals for telitacicept in China, orphan-drug and IND-related regulatory actions, Phase III autoimmune studies in myasthenia gravis and Sjögren's syndrome, and oncology data in HER2-expressing urothelial, gastric and other solid tumors. RemeGen also reports collaborations that extend development or commercialization rights for selected pipeline assets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.